Product Description
Alefacept (Amevive®, Astellas Pharma US, Inc.) is a full dimeric human fusion protein, which consists of an extracellular portion of the human leukocyte function antigen-3 (LFA-3) fused to the Fc portion of immunoglobulin G1. Alefacept is the first biological agent approved by the US Food and Drug Administration (FDA) for the treatment of moderate to severe chronic plaque psoriasis. It is a full human fusion protein binding to CD2 on T cells. With its dual mechanism of action, alefacept blocks the interaction between the leukocyte-function-associated antigen (LFA)-3 and CD2 and thereby impedes the activation and proliferation of T cells. (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2386357/)
Mechanisms of Action: LFA3 Inhibitor,CD2 Inhibitor
Novel Mechanism: No
Modality: Fusion Protein
Route of Administration: Intramuscular,Intravenous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Canada | Chile | Peru | United Kingdom
Approved Indications: None
Known Adverse Events: None
Company: Astellas Pharma
Company Location: NEW YORK NY 10005
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia
Active Clinical Trial Count: 1
Highest Development Phases
Phase 1: Crohn Disease
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| HSC20200410H | P1 |
Not yet recruiting |
Crohn Disease |
2018-04-17 |